The U.S. API market was valued at USD 33.19 billion in 2023 and is projected to reach USD 60.89 billion by 2031, growing at a CAGR of 7.88% from 2024 to 2031. Growth is fueled by the rising prevalence of chronic and genetic diseases, increased development of biologics and biosimilars, expansion by pharma companies, and advances in manufacturing technologies.
Click- https://www.marketsandata.com/industry-reports/united-states-active-pharmaceutical-ingredient-market
Key Growth Drivers:
- Rising Disease Burden: High rates of arthritis, diabetes, and cancer are boosting demand for safe and effective drugs, increasing the need for APIs.
- Biologics & Biosimilars: Clinical trials and FDA approvals for innovative biologic therapies are expanding API demand. Health systems are also promoting cost-effective biosimilars.
- Pharmaceutical Activity: Companies like AbbVie and Adamas Pharmaceuticals are ramping up operations, with new drug launches and facility expansions strengthening domestic API production.
- Technological Innovation: Adoption of continuous manufacturing and personalized medicine is enhancing production efficiency and product quality.
- Post-COVID Measures: Pandemic-induced supply chain disruptions prompted U.S. efforts to localize API production, reducing reliance on overseas suppliers.
Latest reports-
https://www.marketsandata.com/industry-reports/united-states-golf-shoes-market
https://www.marketsandata.com/industry-reports/aircraft-component-market
Contact
Mr. Vivek Gupta
5741 Cleveland street,
Suite 120, VA beach, VA, USA 23462
Tel: +1 (757) 343–3258
Email: info@marketsandata.com
Website: https://www.marketsandata.com
Comments
0 comment